Project Grant R01HL185906
Award Date 8/15/26
Completion Date 4/30/30
Dollars Obligated $500K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $950,550 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop translational magnetic resonance imaging technologies that visualize sodium accumulation and lymphatic physiology in lymphedema and lipedema. The research program, titled "Visualizing Sodium in Lymphatic Disease: A Translational Path," pursues three integrated translational goals: understanding disease...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $404,424 to Texas A&M Engineering Experiment Station on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop an extracellular matrix–based lymphatic patch with valved pre-collectors that restores lymphatic function and supports unidirectional lymph flow. The project addresses a gap in current regenerative approaches that promote lymphangiogenesis but fail to engineer larger...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Tulane University (The Administrators of Tulane Educational Fund) $1,312,424 on April 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize cardiometabolic responses to testosterone in females and estrogen in males and to develop a therapeutic strategy protecting the vasculature while preserving metabolic benefits. The research will investigate how the G protein-coupled estrogen...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $117,552 on January 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of lymphatic endothelial alpha globin in heart failure progression. The research examines how alpha globin expression in lymphatic endothelial cells mediates cardiac remodeling and chronic inflammation in cardiometabolic heart failure. Using genetically modified mice with inducible alpha globin...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $109,696 on June 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a postdoctoral research fellow's transition to scientific independence through mentored investigation of apelin receptor signaling in lymphatic vessel function. The project, titled "The Role of Apelin Receptor Signaling in Lymphatic Vessel," will characterize how the apelin...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $618,352 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanical regulation of endothelial lipid droplet metabolism and its role in vascular dysfunction. The research examines how oscillatory shear stress suppresses triglyceride hydrolysis by inactivating the transcription factor FOXO1, leading to lipid droplet accumulation in...
- The National Heart, Lung, and Blood Institute awarded the Oklahoma Medical Research Foundation $676,865 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate S1PR1 signaling in lymphatic vasculature and its role in tertiary lymphoid organ formation and inflammatory bowel disease pathology. The research will test the hypothesis that S1PR1 deficiency in lymphatic endothelial cells promotes the formation of functionally protective tertiary lymphoid organs...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $732,705 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how cellular reductive state regulates inflammation resolution in atherosclerotic disease. The recipient will determine the influence of changing glutathione ratios (GSH:GSSG) on protein glutathionylation driving MERTK signaling in efferocytosis, the process by which...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $842,500 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of cell-specific programmed death-ligand-1 (PD-L1) in cardiac pathophysiology following ischemic injury and in immune checkpoint inhibitor-mediated cardiotoxicity. The research examines how PD-L1 expression in fibroblasts and myeloid cells regulates repair and...